Limpar
4 resultados

Acesso aberto

Tipo do recurso

Ano de criação

Produção nacional

Revisado por pares

Áreas

Idioma

Editores

Artigo Revisado por pares

Leslie Nitsche, Maria Terradas-Terradas, Kristina Kirschner, Katrin Ottersbach,

The endothelial-to-haematopoietic transition (EHT) gives rise to the first murine haematopoietic stem cells (HSCs) in the aorta-gonads-mesonephros (AGM) region around E10.5. While our understanding of the transcriptional networks regulating HSC emergence is ever-increasing, the mechanisms governing the EHT process are still being investigated. The transcription factor Gata3, whose function has previously been characterized in the sympathetic nervous system AGM niche, is expressed directly in the haemogenic ...

Tópico(s): MicroRNA in disease regulation

2022 - Elsevier BV | Experimental Hematology

Artigo Acesso aberto Revisado por pares

Sha Li, Anne‐Louise Latif, Ashley Newcombe, Kathryn Gilrory, Neil Robertson, Darren Finlay, Xue Lei, Helen Stewart, Karina Barbosa, John Cole, Maria Terradas-Terradas, Loveena Rishi, Lynn McGarry, Claire McKeeve, Claire Reid, William Clark, Joana Campos, Kristina Kirschner, Jonathan Lopez, Jun-Ichi Sakamaki, Jennifer P. Morton, Kevin M. Ryan, Stephen W. G. Tait, Sheela A. Abraham, Tessa L. Holyoake, Brian Higgins, Xu Huang, Mhairi Copland, Tim Chevassut, Ani Deshpande, Karen Keeshan, Peter D. Adams,

Acute Myeloid Leukemia (AML) is a typically-lethal molecularly heterogeneous disease, with few broad-spectrum therapeutic targets. Unusually, over 90% of AML patients retain wild type TP53, encoding pro-apoptotic tumor suppressor p53. However, wild-type p53 functions are frequently suppressed by MDM2, an E3 ubiquitin ligase that targets p53 for proteasomal degradation. MDM2 inhibitors (MDM2i), which activate wild-type p53, show encouraging pre-clinical activity, but limited clinical activity. In an ...

Tópico(s): Multiple Myeloma Research and Treatments

2020 - Elsevier BV | Experimental Hematology